Is Alnylam Pharmaceuticals Inc halal to invest in?

As of July 2026, Alnylam Pharmaceuticals Inc ALNY is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.

Is Alnylam Pharmaceuticals Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Alnylam Pharmaceuticals Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Alnylam Pharmaceuticals Inc?

Muslim investors may consider investing in Alnylam Pharmaceuticals Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Alnylam Pharmaceuticals Inc classified as HALAL?

Musaffa determines the Shariah status of Alnylam Pharmaceuticals Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Alnylam Pharmaceuticals Inc updated?

The Shariah compliance status of Alnylam Pharmaceuticals Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Alnylam Pharmaceuticals Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Alnylam Pharmaceuticals Inc?

You can check the latest Shariah compliance status of Alnylam Pharmaceuticals Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

ALNY Shariah Compliance

Screening Methodology: AAOIFI

As of July 2026, Alnylam Pharmaceuticals Inc is classified as halal.

HALAL

Report Source: 2026 1st Quarter Report

Alnylam Pharmaceuticals Inc. Stock Analysis ALNY

United States Health Care Large Cap Report: Q1, 2026

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company is headquartered in Cambridge, Massachusetts and currently employs 2,500 full-time employees. The company went IPO on 2004-05-28. The firm is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. The company is developing Cemdisiran to treat complement-mediated diseases.

Key Statistics of Alnylam Pharmaceuticals Inc (ALNY)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$267.00$273.72

Today's Open

$270.84

Volume

1.36M

P/E Ratio (TTM)

115.50

52 Week Range

$266.27$495.55

Market Cap

43.19B

Avg. Volume

1.56M

Dividend Yield

Financial Metrics & Statements of Alnylam Pharmaceuticals Inc (ALNY)

Super Investors Invested in Alnylam Pharmaceuticals Inc (ALNY)

FAQ's for Alnylam Pharmaceuticals Inc (ALNY)

As of July 2026, Alnylam Pharmaceuticals Inc ALNY is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Alnylam Pharmaceuticals Inc using these criteria to determine its compliance status.
Muslim investors may consider investing in Alnylam Pharmaceuticals Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
Musaffa determines the Shariah status of Alnylam Pharmaceuticals Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
The Shariah compliance status of Alnylam Pharmaceuticals Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
You can check the latest Shariah compliance status of Alnylam Pharmaceuticals Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.